share_log

华润双鹤(600062.SH):DC10190胶囊获得药物临床试验批准通知书

China Resources Double-Crane Pharmaceutical (600062.SH): DC10190 capsule has received the drug clinical trial approval notice.

Gelonghui Finance ·  Dec 26, 2024 01:15

Gelonghui reported on December 26 that China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary Peking Double-Crane Run Technology Co., Ltd. received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the DC10190 capsules. The DC10190 capsules are intended for the treatment of patients with advanced or metastatic solid tumors and are a type 1 new drug that has not yet been marketed domestically or internationally.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment